Uncommon Pathogens Causing Hospital-Acquired Infections in Postoperative Cardiac Surgical Patients
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Proteus Vulgaris
48 Monte Carlo Crescent Kyalami Business Park Kyalami, Johannesburg, 1684, RSA Tel: +27 (0)11 463 3260 Fax: + 27 (0)86 557 2232 Email: [email protected] www.thistle.co.za Please read this section first The HPCSA and the Med Tech Society have confirmed that this clinical case study, plus your routine review of your EQA reports from Thistle QA, should be documented as a “Journal Club” activity. This means that you must record those attending for CEU purposes. Thistle will not issue a certificate to cover these activities, nor send out “correct” answers to the CEU questions at the end of this case study. The Thistle QA CEU No is: MT- 16/009 Each attendee should claim THREE CEU points for completing this Quality Control Journal Club exercise, and retain a copy of the relevant Thistle QA Participation Certificate as proof of registration on a Thistle QA EQA. MICROBIOLOGY LEGEND CYCLE 41 ORGANISM 3 Proteus Vulgaris Proteus Vulgaris is a rod shaped Gram-Negative chemoheterotrophic bacterium. The size of the individual cells varies from 0.4 to 0.6 micrometers by 1.2 to 2.5 micrometers. P. vulgaris possesses peritrichous flagella, making it actively motile. It inhabits the soil, polluted water, raw meat, gastrointestinal tracts of animals and dust. In humans, Proteus species most frequently cause urinary tract infections, but can also produce severe abscesses and is widely associated with nosocomial infections. Isolation of Organism With basic microbiological technique, samples believed to contain P. vulgaris are first incubated on nutrient agar to form colonies. To test the Gram-Negative and oxidase-negative characteristics of Enterobacteriaceae, Gram stains and oxidase tests are performed. -
Helicobacter Pylori Infection and Its Potential Association with Idiopathic
Journal of Immunology and Infectious Diseases Volume 2 | Issue 2 ISSN: 2394-6512 Research Article Open Access Helicobacter pylori Infection and its Potential Association with Idiopathic Hypercalciuric Urolithiasis in Pediatric Patients Ali AM*1, Abdelaziz SS2 and Elkhatib WF3,4 1Department of Pediatrics, International Islamic Center for Population Studies and Research, Faculty of Medicine, Al-Azhar University, Cairo, Egypt 2Department of Urology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt 3Department of Microbiology & Immunology, Faculty of Pharmacy, Ain Shams University, African Union Organization St. Abbassia, Cairo, Egypt 4Department of Pharmacy Practice, School of Pharmacy, Hampton University, Kittrell Hall Hampton, Virginia, USA *Corresponding author: Ali AM, Department of Pediatrics, Faculty of Medicine, Al-Azhar University, Cairo, Egypt, Postal Code: 31991, Dr. Noor Mohammad Khan General Hospital, Fax: +966713221417, Tel: +966556847829, E-mail: [email protected] Citation: Ali AM, Abdelaziz SS, Elkhatib WF (2014) Helicobacter pylori Infection and its Potential Association with Idiopathic Hypercalciuric Urolithiasis in Pediatric Patients. J Immunol Infect Dis 2(2): 202. doi: 10.15744/2394-6512.1.203 Received Date: September 24, 2014 Accepted Date: January 05, 2015 Published Date: January 09, 2015 Abstract Objectives: To evaluate the role of Helicobacter pylori infection in the pathogenesis of idiopathic hypercalciuric urolithiasis. Design & Setting: Randomized longitudinal controlled study was carried out at Al-Azhar University Hospitals in Cairo and Dommiat, Egypt as well as at Noor Khan General Hospital in Hafer Al-Baten, Saudi Arabia. Participants: A total of 150 patients categorized into 100 cases (urolithiasis-positive) with urinary stone disease, aged from 5 to 18 years, and met the characteristics of idiopathic urolithiasis in children as well as 50 controls (urolithiasis-negative) that had relatively similar demographic criteria except for idiopathic urolithiasis. -
Sequencing of Five Poultry Strains Elucidates Phylogenetic Relationships and Divergence in Virulence Genes in Morganella Morganii
Preprint: Please note that this article has not completed peer review. Sequencing of five poultry strains elucidates phylogenetic relationships and divergence in virulence genes in Morganella morganii CURRENT STATUS: UNDER REVIEW Nicola Palmieri Veterinarmedizinische Universitat Wien Claudia Hess Veterinarmedizinische Universitat Wien Michael Hess Veterinarmedizinische Universitat Wien Merima Alispahic Veterinarmedizinische Universitat Wien [email protected] Author ORCiD: https://orcid.org/0000-0002-2347-2030 DOI: 10.21203/rs.3.rs-21281/v1 SUBJECT AREAS Epigenetics & Genomics KEYWORDS Morganella morganii, poultry, NGS data, MALDI-TOF MS, antimicrobial resistance, virulence genes, phylogeny 1 Abstract Background M. morganii is a bacterium frequently associated with urinary infections in humans. While many human strains are sequenced, only the genomes of few poultry strains are available. Here, we performed a detailed characterization of five highly resistant Morganella morganii strains isolated in association with Escherichia coli from diseased domestic Austrian poultry flocks, namely geese, turkeys and chicken layers. Additionally, we sequenced the genomes of these strains by NGS and analyzed phylogenetic clustering, resistance and virulence genes in the context of host-specificity. Results Two strains were identified to be Extended Spectrum Beta Lactamase (ESBL) and one as AmpC beta- lactamases (AMP-C) phenotype, while two were ESBL negative. By integrating the genome sequences of these five poultry strains with all the available M. morganii genomes, we constructed a phylogenetic tree that clearly separates the Morganella genus into two clusters (M1 and M2), which approximately reflect the proposed subspecies classification ( morganii and sibonii ). Additionally, we found no association between phylogenetic structure and host, suggesting interspecies transmission. All five poultry strains contained genes for resistance to aminocoumarins, beta-lactams, colistin, elfamycins, fluoroquinolones, phenicol, rifampin and tetracycline. -
Cycle 37 Organism 5
P.O. Box 131375, Bryanston, 2074 Ground Floor, Block 5 Bryanston Gate, 170 Curzon Road Bryanston, Johannesburg, South Africa www.thistle.co.za Tel: +27 (011) 463 3260 Fax: +27 (011) 463 3036 Fax to Email: + 27 (0) 86-557-2232 e-mail : [email protected] Please read this section first The HPCSA and the Med Tech Society have confirmed that this clinical case study, plus your routine review of your EQA reports from Thistle QA, should be documented as a “Journal Club” activity. This means that you must record those attending for CEU purposes. Thistle will not issue a certificate to cover these activities, nor send out “correct” answers to the CEU questions at the end of this case study. The Thistle QA CEU No is: MT-2015/009. Each attendee should claim THREE CEU points for completing this Quality Control Journal Club exercise, and retain a copy of the relevant Thistle QA Participation Certificate as proof of registration on a Thistle QA EQA. MICROBIOLOGY LEGEND CYCLE 37 ORGANISM 5 Morganella morganii Historical identification Morganella morganii was first described by a British bacteriologist H. de R. Morgan in 1906 as Morgan's bacillus. Morgan isolated the bacterium from stools of infants who were noted to have had "summer diarrhea". Later in 1919, Winslow et al. named Morgan's bacillus, Bacillus morganii. In 1936, though, Rauss renamed B. morganii as Proteus morganii. Fulton, in 1943, showed that B. columbensis and P. morganii were the same and defined the genus Morganella, due to the DNA-DNA hybridization. However in 1962, a review article by Ewing reported that M. -
2021 ECCMID | 00656 in Vitro Activities of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales
IHMA In Vitro Activities of Ceftazidime-avibactam and Comparator Agents against Enterobacterales and 2122 Palmer Drive 00656 Schaumburg, IL 60173 USA Pseudomonas aeruginosa from Israel Collected Through the ATLAS Global Surveillance Program 2013-2019 www.ihma.com M. Hackel1, M. Wise1, G. Stone2, D. Sahm1 1IHMA, Inc., Schaumburg IL, USA, 2Pfizer Inc., Groton, CT USA Introduction Results Results Summary Avibactam (AVI) is a non-β- Table 1 Distribution of 2,956 Enterobacterales from Israel by species Table 2. In vitro activity of ceftazidime-avibactam and comparators agents Figure 2. Ceftazidime and ceftazidime-avibactam MIC distribution against 29 . Ceftazidime-avibactam exhibited a potent lactam, β-lactamase inhibitor against Enterobacterales and P. aeruginosa from Israel, 2013-2019 non-MBL carbapenem-nonsusceptible (CRE) Enterobacterales from Israel, antimicrobial activity higher than all Organism N % of Total mg/L that can restore the activity of Organism Group (N) %S 2013-2019 comparator agents against all Citrobacter amalonaticus 2 0.1% MIC90 MIC50 Range ceftazidime (CAZ) against Enterobacterales (2956) 20 Enterobacterales from Israel (MIC90, 0.5 Citrobacter braakii 5 0.2% Ceftazidime-avibactam 99.8 0.5 0.12 ≤0.015 - > 128 Ceftazidime Ceftazidime-avibactam organisms that possess Class 18 mg/L; 99.8% susceptible). Citrobacter freundii 96 3.2% Ceftazidime 70.1 64 0.25 ≤0.015 - > 128 A, C, and some Class D β- Cefepime 71.8 > 16 ≤0.12 ≤0.12 - > 16 16 . Susceptibility to ceftazidime-avibactam lactmase enzymes. This study Citrobacter gillenii 1 <0.1% Meropenem 98.8 0.12 ≤0.06 ≤0.06 - > 8 increased to 100% for the Enterobacterales Amikacin 95.4 8 2 ≤0.25 - > 32 14 examined the in vitro activity Citrobacter koseri 123 4.2% when MBL-positive isolates were removed Colistin (n=2544)* 82.2 > 8 0.5 ≤0.06 - > 8 12 of CAZ-AVI and comparators Citrobacter murliniae 1 <0.1% Piperacillin-tazobactam 80.4 32 2 ≤0.12 - > 64 from analysis. -
경추 척수 손상 환자에서 발생한 Providencia Rettgeri 패혈증 1예 조현정·임승진·천승연·박권오·이상호·박종원·이진서·엄중식 한림대학교 의과대학 내과학교실
Case Report Infection & DOI: 10.3947/ic.2010.42.6.428 Chemotherapy Infect Chemother 2010;42(6):428-430 경추 척수 손상 환자에서 발생한 Providencia rettgeri 패혈증 1예 조현정·임승진·천승연·박권오·이상호·박종원·이진서·엄중식 한림대학교 의과대학 내과학교실 A Case of Providencia rettgeri Sepsis in a Patient with Hyun-Jung Cho, Seung-Jin Lim, Seung-Yeon Chun, Cervical Cord Injury Kwon-Oh Park, Sang-Ho Lee, Jong-Won Park, Jin- Seo Lee, and Joong-Sik Eom Providencia rettgeri is a member of Enterobacteriacea that is known to cause Department of Internal Medicine, Hallym Univer- urinary tract infection (UTI), septicemia, and wound infections, especially in sity College of Medi cine, Seoul, Korea immunocompromised patients and in those with indwelling urinary catheters. We experienced a case of UTI sepsis by Providencia rettgeri in a patient with spinal cord injury. The patient had only high fever without urinary symptoms or signs after high dose intravenous methylprednisolone. The laboratory results showed leukocytosis (21,900/μL, segmented neutrophils 91.1%) and pyuria. Cefepime was given empirically and it was switched to oral trimethoprim-sulfamethoxazole because P. rettgeri was identified from blood and urine culture which was susceptible to TMP-SMX. The patient was improved clinically but P. rettgeri was not eradicated microbiologically. To the best of our knowledge, this is the first case report on sepsis caused by Providencia rettgeri in Korea. Key Words: Providencia rettgeri, Sepsis, Urinary tract infection Introduction The genus Providencia is a member of the Enterobacteriaceae family which commonly dwells in soil, water, and sewage [1, 2]. Providencia rettgeri is one of five Providencia species that is known to cause various infections, especially the Copyright © 2010 by The Korean Society of Infectious Diseases | Korean urinary tract infection (UTI) [3]. -
Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org). -
Investigating the Biological and Mechanical Performance of Cranberry-Modified Silicone Materials for Use in Implantable Medical Devices
Investigating the biological and mechanical performance of cranberry-modified silicone materials for use in implantable medical devices By Louis Briggs Department of Chemical Engineering McGill University, Montreal August 2014 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Master of Engineering © Louis Briggs 2014 Abstract Catheter associated urinary tract infections (CAUTIs) are the second most common type of hospital acquired infection in North America with over a million cases reported each year. This high incidence rate, together with the dissemination of antibiotic resistant uropathogens has resulted in much interest in the development of preventative measures within the research community. The consumption of Vaccinium macrocarpon, the North American cranberry, has been linked with the prevention of bacterial infections in the urinary tract for over 100 years. The McGill Biocolloids and Surfaces Laboratory has shown that cranberry derived materials (CDMs) can inhibit bacterial adherence to surfaces, impair bacterial motility, and influence various bacterial virulence functions. It is therefore hypothesized that cranberries and CDMs could prevent the development of CAUTIs via the disruption of various stages of pathogenesis. Herein, we report on the bioperformance of cranberry impregnated biomedical grade silicone against the biofilms formed by Proteus mirabilis, a clinically relevant uropathogen. In addition, the mechanical performance of this cranberry-silicone hybrid material is studied. First, the release of bioactive cranberry materials into an aqueous environment is demonstrated in lysogeny broth using a spectrophotometric method. Second, the ultimate tensile strength, elongation at break, storage modulus, and contact angle of CDM impregnated silicone are reported. Finally, the ability of P. -
Morganella Morganii
Morganella morganii: an uncommon cause of diabetic foot infection Tran Tran, DPM, Jana Balas, DPM, & Donald Adams, DPM, FACFAS MetroWest Medical Center, Framingham, MA INTRODUCTION LITERATURE REVIEW RESULTS RESULTS (Continued) followed in both wound care and podiatry clinic. During his Diabetic foot ulcers are at significant risk for causing Gram- Morganella morganii is a facultative gram negative anaerobic The patient was admitted to the hospital for intravenous stay in a rehabilitation facility, the patient developed a left negative bacteraemia and can result in early mortality. bacteria belongs to the Enterobacteriacea family and it is Cefazolin and taken to the operating room the next day heel decubitus ulcer. The left second digit amputation site Morganella morganii is a facultative Gram-negative anaerobe beta-lactamase inducible. It becomes important when it where extensive debridement of nonviable bone and soft has greatly reduced in size, with most recent measurements commonly found in the human gastrointestinal tract as manifests as an opportunistic pathogenic infection elsewhere tissue lead to amputation of the left second digit (Image 1). being 1.5 x 1.0 x 0.4 cm with granular base and the decubitus normal flora but can manifest in urinary tract, soft tissue, and in the body. The risk of infection is particularly high when a Gram stain showed gram negative growth and antibiotics ulcer is stable. abdominal infections. M. morganii is significant as an patient becomes neutropenic that can make a patient more were changed to Zosyn. Intraoperative deep tissue cultures infectious opportunistic pathogen. In diabetics it is shown to susceptible to bacteremia. Immunocompromised patients are grew M. -
The LOUISIANA ANTIBIOGRAM Louisiana Antibiotic Resistance 2014
The LOUISIANA ANTIBIOGRAM Louisiana Antibiotic Trends in Antibiotic Resistance Resistance 2014 in Louisiana 2008 Zahidul Islam MBBS, MPH, Raoult C Ratard MD MPH Contributors to this report: Lauren Kleamenakis MPH, Anup Subedee MD MPH and Raoult Ratard MD MPH. This report covers bacteria causing severe human infections and the antibiotics used to treat those infections. Resistance to other antimicrobials (antivirals, antifungals and anti-parasitic drugs) are not included for lack of systematic reporting and collection of comprehensive data. Contents 1-Introduction ............................................................................................................................................... 3 1.1-Bacterial resistance to antibiotics is a major threat to human health .................................................. 3 1.2-Tracking resistance patterns is a major action in the fight against antibiotic resistance ..................... 3 2-Methods ..................................................................................................................................................... 3 2.1-Active surveillance .............................................................................................................................. 3 2.2-Antibiogram collection ....................................................................................................................... 3 2.3-Analysis .............................................................................................................................................. -
Original Article COMPARISON of MAST BURKHOLDERIA CEPACIA, ASHDOWN + GENTAMICIN, and BURKHOLDERIA PSEUDOMALLEI SELECTIVE AGAR
European Journal of Microbiology and Immunology 7 (2017) 1, pp. 15–36 Original article DOI: 10.1556/1886.2016.00037 COMPARISON OF MAST BURKHOLDERIA CEPACIA, ASHDOWN + GENTAMICIN, AND BURKHOLDERIA PSEUDOMALLEI SELECTIVE AGAR FOR THE SELECTIVE GROWTH OF BURKHOLDERIA SPP. Carola Edler1, Henri Derschum2, Mirko Köhler3, Heinrich Neubauer4, Hagen Frickmann5,6,*, Ralf Matthias Hagen7 1 Department of Dermatology, German Armed Forces Hospital of Hamburg, Hamburg, Germany 2 CBRN Defence, Safety and Environmental Protection School, Science Division 3 Bundeswehr Medical Academy, Munich, Germany 4 Friedrich Loeffler Institute, Federal Research Institute for Animal Health, Jena, Germany 5 Department of Tropical Medicine at the Bernhard Nocht Institute, German Armed Forces Hospital of Hamburg, Hamburg, Germany 6 Institute for Medical Microbiology, Virology and Hygiene, University Medicine Rostock, Rostock, Germany 7 Department of Preventive Medicine, Bundeswehr Medical Academy, Munich, Germany Received: November 18, 2016; Accepted: December 5, 2016 Reliable identification of pathogenic Burkholderia spp. like Burkholderia mallei and Burkholderia pseudomallei in clinical samples is desirable. Three different selective media were assessed for reliability and selectivity with various Burkholderia spp. and non- target organisms. Mast Burkholderia cepacia agar, Ashdown + gentamicin agar, and B. pseudomallei selective agar were compared. A panel of 116 reference strains and well-characterized clinical isolates, comprising 30 B. pseudomallei, 20 B. mallei, 18 other Burkholderia spp., and 48 nontarget organisms, was used for this assessment. While all B. pseudomallei strains grew on all three tested selective agars, the other Burkholderia spp. showed a diverse growth pattern. Nontarget organisms, i.e., nonfermentative rod-shaped bacteria, other species, and yeasts, grew on all selective agars. -
Clinical Antibiotic Guidelines†
CLINICAL ANTIBIOTIC GUIDELINES† ACYCLOVIR IV*/PO *RESTRICTED TO ANTIBIOTIC FORM Predictable activity: Unpredictable activity: No activity: Herpes Simplex Cytomegalovirus Epstein Barr Virus Herpes Zoster Indicated: IV: 1. Therapy for suspected or documented Herpes simplex encephalitis 2. Therapy for suspected or documented Herpes simplex infection of a newborn or immunocompromised patient 3. Therapy for primary varicella infection in immunocompromised patients 4. Therapy for severe or disseminated varicella-zoster infections in immunocompromised or immunocompetent patient 5. Therapy for primary genital herpes with neurologic complications Oral: 1. Therapy for primary Herpes simplex infections (oral/genital) 2. Suppressive (preventative) therapy for recurrent (³ 6 episodes/year) severe Herpes simplex infections (oral/genital) 3. Episodic therapy for recurrent (³ 6 episodes/year) Herpes simplex genital infections (initiate within 24 hours of prodrome onset) 4. Prophylaxis for HSV in bone marrow transplants where patient is seropositive 5. Therapy and suppressive therapy for Eczema Herpeticum 6. Therapy for varicella-zoster infections in immunocompetent and immunocompromised patients (if not severe) 7. Therapy for primary varicella infections in pregnancy 8. Therapy for varicella in immunocompetent patients > 13 years old (initiate within 24 hours of rash onset) 9. Therapy for varicella in patients < 13 years old (initiate within 24 hours of rash onset) if there is a chronic cutaneous or pulmonary disorder, long term salicylate therapy, or short, intermittent or aerosolized corticosteroid use Not Indicated: 1. Therapy for acute Epstein-Barr infections (acute mononucleosis) 2. Therapy for documented CMV infections CLINICAL ANTIBIOTIC GUIDELINES† AMIKACIN RESTRICTED TO ANTIBIOTIC FORM Predictable activity: Unpredictable activity: No activity: Enterobacteriaceae Staphylococcus spp Streptococcus spp Pseudomonas spp Enterococcus spp some Mycobacterium spp Alcaligenes spp Anaerobes Indicated: 1.